Panaji Journal

(Albany, US) September 29, 2026 – DelveInsight’s “IPSC Derived NK Cells Pipeline Insight, 2026” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in the iPSC-derived NK cells pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the iPSC-Derived NK Cells Treatment Landscape @ https://www.delveinsight.com/report-store/ipsc-derived-nk-cells-pipeline-insight

Key Takeaways from the iPSC-Derived NK Cells Pipeline Report

• DelveInsight’s iPSC-derived NK cells pipeline report depicts a robust space with 12+ active players working to develop 15+ pipeline therapies in this drug class.

• The leading iPSC-Derived NK Cells Companies include Century Therapeutics, Inc., Fate Therapeutics, Cartherics Pty Ltd, Nuwacell Biotechnologies Co., Ltd, HebeCell, BrightPath Biotherapeutics, Qihan Biotech, and others.

• Promising iPSC-Derived NK Cells Pipeline Therapies such as CNTY-101, FT522, CTH-401, NCR300, HC101a, BP 2201, QN-139b, and others.

• The companies which have their drug candidates in the most advanced stage, i.e. Phase I/II, include Century Therapeutics, Inc.

Gain in-depth knowledge of key iPSC-derived NK cells clinical trials, emerging drugs, and market opportunities @ iPSC-Derived NK Cells Clinical Trials Assessment

iPSC-Derived NK Cells Overview

iPSC-derived NK cells are natural killer immune cells generated from Induced Pluripotent Stem Cells (iPSCs), providing a scalable and standardized platform for next-generation cancer immunotherapy. They are produced through a controlled differentiation process in which iPSCs first develop into CD34⁺ hematopoietic progenitor cells and then mature into functional NK cells under cytokine stimulation, particularly Interleukin-15. During maturation, the cells express key cytotoxic molecules such as granzyme B (GZMB) and perforin (PRF1), enabling them to recognize and eliminate malignant cells — especially those lacking Human Leukocyte Antigen class I expression, a common immune-evasion strategy used by tumors. Compared with donor-derived NK cells, iPSC-derived NK cells minimize donor variability and support large-scale “off-the-shelf” manufacturing, while their stable genetic background allows precise engineering, including integration of Chimeric Antigen Receptor (CAR) constructs to enhance tumor targeting.

During differentiation, these cells undergo a structured maturation process that mirrors the natural development of natural killer cells, beginning with embryoid bodies that generate CD34⁺CD45⁺ hematopoietic progenitors, which gradually differentiate into NK lineage cells. As maturation progresses, the cells transition from loose aggregates to compact lymphoid populations with greater cytoplasmic complexity and granularity, acquiring markers such as CD56, CD161, and CD94 before developing a mature phenotype defined by CD56⁺CD16⁺CD3⁻ expression and activating receptors like NKp46. Morphologically, mature cells exhibit a high nucleus-to-cytoplasm ratio and contain azurophilic cytotoxic granules; functionally, they form immunological synapses with target cells and release perforin and granzymes, a process supported by JAK-STAT5 signaling pathway activation that promotes NK-cell survival and activity.

As a therapeutic platform, iPSC-derived NK cells are being widely explored for both hematologic and solid tumors, with scalable production enabling standardized cell therapies for diseases such as leukemia and lymphoma, as well as other treatment-resistant malignancies. These engineered immune cells show potent cytotoxic activity against tumors that downregulate HLA class I molecules, including lung cancer, ovarian cancer, melanoma, myeloid leukemia, and hepatocellular carcinoma. Genetic engineering approaches, particularly CAR integration, can further enhance their tumor specificity and persistence, and these NK cells may act synergistically with monoclonal antibodies and immune checkpoint inhibitors to strengthen antitumor immune responses, making them a promising strategy in next-generation cellular immunotherapy.

iPSC-Derived NK Cells Emerging Drugs Profile

• CNTY-101: Century Therapeutics, Inc.

CNTY-101 is an investigational, off-the-shelf cell therapy developed by Century Therapeutics for the treatment of B-cell mediated autoimmune diseases. Derived from induced pluripotent stem cells (iPSCs) and engineered into CD19-targeted chimeric antigen receptor natural killer (CAR-NK) cells, it selectively depletes CD19-positive B cells implicated in diseases such as systemic lupus erythematosus. CNTY-101 incorporates genetic modifications to enhance persistence, functionality, and resistance to immune rejection, and as an allogeneic product it aims to provide a scalable, readily available alternative to autologous cell therapies. Currently, CNTY-101 is being evaluated in a Phase I/II trial in patients with B-cell mediated autoimmune diseases.

• FT522: Fate Therapeutics

FT522 is an investigational, off-the-shelf CAR-NK cell therapy derived from iPSCs and developed by Fate Therapeutics, engineered with a Chimeric Antigen Receptor (CAR) that targets CD19 expressed on malignant B cells to enable selective recognition and destruction of tumor cells. It also incorporates a proprietary Alloimmune Defense Receptor (ADR) designed to improve persistence by eliminating activated alloreactive immune cells that could otherwise reject the therapy. Manufactured as a cryopreserved allogeneic product, FT522 supports scalable production and immediate availability without patient-specific cell collection, aiming to deliver potent antitumor activity with improved durability and safety compared with conventional approaches. Currently, FT522 is being evaluated in Phase I clinical trials for the treatment of relapsed/refractory B-cell lymphoma.

The iPSC-Derived NK Cells Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing iPSC-derived NK cell therapies, with aggregate therapies developed by each company.

• It assesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage development.

• iPSC-Derived NK Cells Companies are involved in targeted therapeutics development, with respective active and inactive (dormant or discontinued) projects.

• iPSC-derived NK cell drugs under development are categorized based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecule type.

• Detailed analysis of collaborations (company-company and company-academia), licensing agreements, mergers and acquisitions, and funding for future advancement in this space.

Uncover critical updates on therapeutic innovations and their potential impact on patients @ iPSC-Derived NK Cells Unmet Needs

iPSC-Derived NK Cells Companies

Century Therapeutics, Inc., Fate Therapeutics, Cartherics Pty Ltd, Nuwacell Biotechnologies Co., Ltd, HebeCell, BrightPath Biotherapeutics, Qihan Biotech, and others.

iPSC-derived NK cells pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

iPSC-Derived NK Cells Products have been categorized under various Molecule types such as:

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Transform your understanding of the iPSC-Derived NK Cells Pipeline! @ iPSC-Derived NK Cells Market Drivers and Barriers, and Future Perspectives

Scope of the iPSC-Derived NK Cells Pipeline Report

• Coverage- Global

• iPSC-Derived NK Cells Companies- Century Therapeutics, Inc., Fate Therapeutics, Cartherics Pty Ltd, Nuwacell Biotechnologies Co., Ltd, HebeCell, BrightPath Biotherapeutics, Qihan Biotech and others.

• iPSC-Derived NK Cells Pipeline Therapies- CNTY-101, FT522, CTH-401, NCR300, HC101a, BP 2201, QN-139b and others.

• iPSC-Derived NK Cells Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• iPSC-Derived NK Cells Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access the Full iPSC-Derived NK Cells Pipeline Analysis Today! @ iPSC-Derived NK Cells Drugs and Companies

Table of Contents

• Introduction

• Executive Summary

• IPSC Derived NK Cells: Overview

• Pipeline Therapeutics

• Comparative Analysis

• Therapeutic Assessment

• IPSC Derived NK Cells: DelveInsight’s Analytical Perspective

• Late Stage Products (Phase III)

• Mid Stage Products (Phase II)

• Early Stage Products (Phase I)

• Preclinical and Discovery Stage Products

• Inactive Products

• IPSC Derived NK Cells Key Companies

• IPSC Derived NK Cells Key Products

• IPSC Derived NK Cells: Unmet Needs

• IPSC Derived NK Cells: Market Drivers and Barriers

• IPSC Derived NK Cells: Future Perspectives and Conclusion

• IPSC Derived NK Cells Analyst Views

• IPSC Derived NK Cells Key Companies

• Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/ipsc-derived-nk-cells-pipeline-insight